CA2717181C - Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions - Google Patents

Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions Download PDF

Info

Publication number
CA2717181C
CA2717181C CA2717181A CA2717181A CA2717181C CA 2717181 C CA2717181 C CA 2717181C CA 2717181 A CA2717181 A CA 2717181A CA 2717181 A CA2717181 A CA 2717181A CA 2717181 C CA2717181 C CA 2717181C
Authority
CA
Canada
Prior art keywords
approximately
patient
formula
paclitaxel
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2717181A
Other languages
English (en)
French (fr)
Other versions
CA2717181A1 (en
Inventor
Frederick H. Hausheer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioNumerik Pharmaceuticals Inc
Original Assignee
BioNumerik Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNumerik Pharmaceuticals Inc filed Critical BioNumerik Pharmaceuticals Inc
Publication of CA2717181A1 publication Critical patent/CA2717181A1/en
Application granted granted Critical
Publication of CA2717181C publication Critical patent/CA2717181C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
CA2717181A 2008-03-14 2008-03-14 Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions Active CA2717181C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/003405 WO2009113983A1 (en) 2008-03-14 2008-03-14 Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions

Publications (2)

Publication Number Publication Date
CA2717181A1 CA2717181A1 (en) 2009-09-17
CA2717181C true CA2717181C (en) 2013-10-15

Family

ID=41065492

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2717181A Active CA2717181C (en) 2008-03-14 2008-03-14 Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions

Country Status (6)

Country Link
EP (1) EP2249825B1 (https=)
JP (1) JP5694782B2 (https=)
AU (1) AU2008352597B2 (https=)
CA (1) CA2717181C (https=)
DK (1) DK2249825T3 (https=)
WO (1) WO2009113983A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11471431B2 (en) * 2010-09-16 2022-10-18 Lantern Pharma Inc. Increasing cancer patient survival time by administration of dithio-containing compounds
CN109619552A (zh) * 2018-12-05 2019-04-16 贾志丹 适用于肿瘤患者的营养治疗型配方及制备方法、用途
CN120078760A (zh) * 2019-03-08 2025-06-03 蓝腾制药公司 治疗患有非小细胞肺癌的女性非吸烟者的方法
CN115040549A (zh) * 2022-06-07 2022-09-13 广东特芯生物科技有限公司 一种用于肿瘤的组合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177263A (en) 1972-02-28 1979-12-04 Research Corporation Anti-animal tumor method
US4657927A (en) 1978-05-04 1987-04-14 Research Corporation Malonato platinum compounds
US4310515A (en) 1978-05-30 1982-01-12 Bristol-Myers Company Pharmaceutical compositions of cisplatin
US4302446A (en) 1979-10-02 1981-11-24 Bristol-Myers Company Pharmaceutical compositions
US4451447A (en) 1980-03-31 1984-05-29 Bristol-Myers Company Pharmaceutical formulations
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4915956A (en) 1987-12-16 1990-04-10 Lyphomed, Inc. Liquid cisplatin formulations
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
JPH0776230B2 (ja) 1992-01-13 1995-08-16 田中貴金属工業株式会社 白金化合物の製造方法
JP2673331B2 (ja) 1993-01-12 1997-11-05 田中貴金属工業 株式会社 光学的に高純度なシス―オキザラート（トランス―１―１，２―シクロヘキサンジアミン）白金（▲ｉｉ▼）
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
IL114852A (en) 1994-08-08 2000-02-29 Debiopharm Sa Pharmaceutically stable preparation of oxaliplatinum
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
DE19617802A1 (de) 1996-05-03 1997-11-06 Basf Ag Verfahren zur heterogen katalysierten Herstellung von Hydroxyalkyl-substituierten Aminoalkinen
US6037336A (en) 1996-09-23 2000-03-14 Bionumerik Pharmaceuticals, Inc. Reducing toxic effects of carboplatin using dithioethers
ES2170414T3 (es) * 1996-09-23 2002-08-01 Bionumerik Pharmaceuticals Inc Reduccion de efectos toxicos del carboplatino usando ditioeteres.
US6160167A (en) 1998-04-21 2000-12-12 Bionumerik Pharmaceuticals, Inc. Mercaptans and disulfides
EP1351677A4 (en) * 2001-01-19 2009-08-19 Bionumerik Pharmaceuticals Inc CANCER TREATMENT METHOD
US6504049B1 (en) 2002-04-30 2003-01-07 Bionumerik Pharmaceuticals, Inc. Process for synthesizing pharmaceutically active disulfide salts
US8710095B2 (en) * 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
US20050256055A1 (en) 2004-05-12 2005-11-17 Hausheer Frederick H Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
EP2004175A4 (en) * 2006-03-16 2010-12-15 Bionumerik Pharmaceuticals Inc COMPOUNDS AND FORMULATIONS FOR INCREASING THE EFFECT OF CANCER AND METHOD FOR THEIR USE
JP6516187B2 (ja) 2015-07-23 2019-05-22 パナソニックＩｐマネジメント株式会社 眠気判定装置、眠気判定方法、眠気判定プログラムおよび記録媒体

Also Published As

Publication number Publication date
AU2008352597B2 (en) 2012-03-08
AU2008352597A1 (en) 2009-09-17
EP2249825A1 (en) 2010-11-17
CA2717181A1 (en) 2009-09-17
EP2249825B1 (en) 2015-10-07
WO2009113983A1 (en) 2009-09-17
EP2249825A4 (en) 2011-10-05
JP5694782B2 (ja) 2015-04-01
JP2011514355A (ja) 2011-05-06
DK2249825T3 (en) 2016-01-11

Similar Documents

Publication Publication Date Title
Qi et al. Salinomycin as a potent anticancer stem cell agent: State of the art and future directions
US20050038113A1 (en) Valproic acid and derivatives for the combinatorial therapeutic treatment of human cancers and for the treatment of tumor metastasis and minimal residual disease
AU2008352603B2 (en) Compositions and methods of use of compounds to increase cancer patient survival time
AU2015314753A1 (en) Human dosing of phosphatase inhibitor
JP2019069969A (ja) 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤
US20090232906A1 (en) Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
CA2717181C (en) Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
AU2010224108A1 (en) Treatment of pancreatic cancer
KR20160003652A (ko) 감마―글루타밀 주기 조절 방법 및 조성물
JP6462582B2 (ja) がんの治療のための方法および組成物
Gomez Rodriguez et al. Synergic effect of anticancer peptide CIGB-552 and Cisplatin in lung cancer models
US20180153870A1 (en) Biperiden for treating cancer
WO2014191989A1 (en) Conjugate of a taxane and biotin and uses thereof
US20230149358A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and hormone therapy agent
CN116390731A (zh) 五氮杂大环状环配合物与激素治疗剂的组合癌症疗法
Ökçesiz et al. Evaluation of toxic effects of statins and their possible role in treatment of cancer
US20230255993A1 (en) Treatment of triple negative breast cancer
US12544347B2 (en) Anti-cancer combination and a method of therapy using the combination
WO2024186961A1 (en) Mitochondria-targeted agents for disease prevention and treatment
WO2023239821A2 (en) Treating cancers with combinations of acylfulvenes with ibrutinib or bortezomib
AU2023235307A1 (en) Combinations comprising metap2 inhibitors for the treatment of cancer
Mohamed Synthesis and biochemical study on the effect of a novel gallium complex on tumor cell Invasion and matrix metalloproteinase activity in vitro.
WO2020229685A1 (en) Combination therapy for proliferative conditions
JP2020515649A (ja) がんを治療するためのｂｃｌ２関連細胞死アゴニストの発現を増加する薬剤
Millard Discovery of novel small molecules targeting cancer cell metabolism

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250120

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250120

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250120

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260212

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260212